- $2.91bn
- $8.08bn
- $3.11bn
- 54
- 73
- 33
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.63 | ||
| PEG Ratio (f) | 0.23 | ||
| EPS Growth (f) | 5,787.52% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.76 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 17.7 | ||
| Price to Sales | 0.97 | ||
| EV to EBITDA | 17.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.54% | ||
| Return on Equity | -10.43% | ||
| Operating Margin | 10.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,860.1 | 2,225.1 | 2,539.3 | 2,743.3 | 3,114.3 | 3,380.06 | 3,692.39 | 11.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +37.28 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility Services segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of 161 surgical facilities comprised of 142 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 31 states, including short-stay surgical hospitals.
Directors
- Wayne DeVeydt CHM (51)
- J. Eric Evans CEO (44)
- David Doherty CFO (49)
- George Goodwin CEX (60)
- Bradley Owens CEX (51)
- Laura Brocklehurst CHO (51)
- Jennifer Baldock EVP (50)
- Anthony Taparo OTH (55)
- Clifford Adlerz DRC (67)
- Blair Hendrix DRC
- T. Devin O'Reilly DRC (47)
- John Deane IND (59)
- Teresa DeLuca IND (55)
- Andrew Kaplan IND (36)
- Patricia Maryland IND (67)
- Brent Turner IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 2nd, 2015
- Public Since
- October 1st, 2015
- No. of Shareholders
- 193
- No. of Employees
- 15,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 128,160,075
- Address
- 310 Seven Springs Way, Suite 500, BRENTWOOD, 37027
- Web
- https://surgerypartners.com/
- Phone
- +1 6152345900
- Auditors
- Ernst & Young LLP
Upcoming Events for SGRY
Surgery Partners Inc Annual Shareholders Meeting
Q2 2025 Surgery Partners Inc Earnings Release
Q3 2025 Surgery Partners Inc Earnings Release
Similar to SGRY
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
What is the Surgery Partners share price?
As of Today at 23:31 UTC, shares in Surgery Partners are trading at $23.94. This share price information is delayed by 15 minutes.
How has the Surgery Partners share price performed this year?
Shares in Surgery Partners last closed at $23.94 and the price had moved by -9.49% over the past 365 days. In terms of relative price strength the Surgery Partners share price has underperformed the S&P500 Index by -19.44% over the past year.
What are the analyst and broker recommendations for Surgery Partners?
The overall consensus recommendation for Surgery Partners is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Surgery Partners dividend yield?
Surgery Partners does not currently pay a dividend.
Does Surgery Partners pay a dividend?
Surgery Partners does not currently pay a dividend.
When does Surgery Partners next pay dividends?
Surgery Partners does not currently pay a dividend.
How do I buy Surgery Partners shares?
To buy shares in Surgery Partners you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Surgery Partners?
As of the previous close price of $23.94, shares in Surgery Partners had a market capitalisation of $3.07bn.
Where are Surgery Partners shares listed?
Here are the trading details for Surgery Partners:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SGRY
What kind of share is Surgery Partners?
Based on an overall assessment of its quality, value and momentum Surgery Partners is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Surgery Partners share price forecast for 2025?
The analyst consensus target price for shares in Surgery Partners is $32.10. That is 34.09% above the last closing price of $23.94.
Analysts covering Surgery Partners currently have a consensus Earnings Per Share (EPS) forecast of $0.93 for the next financial year.
Find out moreWhat is the trend in the Surgery Partners share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Surgery Partners. Over the past six months, its share price has outperformed the S&P500 Index by +3.18%.
As of the last closing price of $23.94, shares in Surgery Partners were trading -6.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Surgery Partners PE Ratio?
The Surgery Partners PE ratio based on its reported earnings over the past 12 months is 22.63. The shares last closed at $23.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Surgery Partners?
Surgery Partners' management team is headed by:
- Wayne DeVeydt - CHM
- J. Eric Evans - CEO
- David Doherty - CFO
- George Goodwin - CEX
- Bradley Owens - CEX
- Laura Brocklehurst - CHO
- Jennifer Baldock - EVP
- Anthony Taparo - OTH
- Clifford Adlerz - DRC
- Blair Hendrix - DRC
- T. Devin O'Reilly - DRC
- John Deane - IND
- Teresa DeLuca - IND
- Andrew Kaplan - IND
- Patricia Maryland - IND
- Brent Turner - IND